PCI-32765: Interim Phase II data

Interim data from 51 evaluable patients in the open-label, international Phase II PCYC-1104-CA trial showed that once-daily 560 mg oral

Read the full 205 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE